We sought to establish a convenient, sensitive next-generation sequencing (NGS) method for genotyping the 26 most commonly mutated leukemiaassociated genes in a single work flow and to optimize this method for low amounts of input template DNA.
oncogene (synonyms: CD110, TPOR); CBL, Cbl proto-oncogene, E3 ubiquitin protein ligase (synonyms: c-Cbl, CBL2, RNF55); RUNX1, runt-related transcription factor 1 (synonyms: AMLCR1, PEBP2A2); TP53, tumor protein p53 (synonyms: LFS1, p53); NPM1, nucleophosmin (nucleolar phosphoprotein B23, numatrin) (synonyms: B23, NPM); TET2, tet methylcytosine dioxygenase 2 (synonym: FLJ20032); ASXL1, additional sex combs like 1 (Drosophila); EZH2, enhancer of zeste homolog 2 (Drosophila) (synonyms: ENX-1, EZH1, KMT6, KMT6A); DNMT3A, DNA (cytosine-5-)-methyltransferase 3 alpha; IDH1, isocitrate dehydrogenase 1 (NADPϩ), soluble; IDH2, isocitrate dehydrogenase 2 (NADPϩ), mitochondrial; SF3B1, splicing factor 3b, subunit 1, 155kDa (synonyms: Hsh155, Prp10, PRPF10, SAP155, SF3b155); SRSF2, serine/arginine-rich splicing factor 2 (synonyms: PR264, SC-35, SC35, SFRS2A); U2AF1, U2 small nuclear RNA auxiliary factor 1 (synonyms: RN, RNU2AF1, U2AF35); ZRSR2, zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 (synonyms: U2AF1-RS2, URP); CEBPA, CCAAT/enhancer binding protein (C/EBP), alpha (synonyms: C/EBP-␣, CEBP); KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (synonym: KRAS1); NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog (synonym: N-ras); KDM6A, lysine (K)-specific demethylase 6A (synonym: UTX). related tyrosine kinase 3), JAK2 (Janus kinase 2), MPL (myeloproliferative leukemia virus oncogene), and CBL (Cbl proto-oncogene, E3 ubiquitin protein ligase); genes encoding transcription and other nuclear factors, such as RUNX1 (runt-related transcription factor 1), TP53 (tumor protein p53), and NPM1 [nucleophosmin (nucleolar phosphoprotein B23, numatrin)]; and genes involved in epigenetic regulation, such as TET2 (tet methylcytosine dioxygenase 2), ASXL1 [additional sex combs like 1 (Drosophila)], EZH2 [enhancer of zeste homolog 2 (Drosophila)], DNMT3A [DNA (cytosine-5-)-methyltransferase 3 alpha], IDH1 [isocitrate dehydrogenase 1 (NADPϩ), soluble], and IDH2 [isocitrate dehydrogenase 2 (NADPϩ), mitochondrial]. None of these aberrations, however, are specific to any particular AML, MDS, MPN, or MDS/ MPN subtype (1) (2) (3) (4) . In addition, mutations in genes involved in the RNA-splicing machinery, such as SF3B1 (splicing factor 3b, subunit 1, 155kDa), SRSF2 (serine/arginine-rich splicing factor 2), U2AF1 [U2 small nuclear RNA auxiliary factor 1 (also known as U2AF35)], and ZRSR2 [zinc finger (CCCH type), RNA-binding motif and serine/arginine rich], have recently been identified in MDS and in chronic myelomonocytic leukemia (CMML), as well as in AML and MPN at lower frequencies (5) (6) (7) . In light of these findings, recent studies have started analyzing data obtained simultaneously from panels of different target genes instead of investigating single genes (8 -13 ) .
We have devised a convenient, sensitive NGS method for simultaneous targeted sequencing of the 26 most commonly mutated genes in AML, MDS, MPN, and MDS/MPN. In addition, we combined this NGS method with whole-genome amplification (WGA) to generate large amounts of template from just 20 ng genomic DNA (gDNA), because patient material required for molecular analyses is often limited in quantity or so valuable that as much material as possible needs to be retained for future use. Because of its high DNA yield and low base pair-incorporation errors, multiple-displacement amplification (MDA) is the most widely used WGA method (14, 15 ) . We have tested the performance of 2 of the most commonly used MDA kits for amplifying samples before NGS analyses and have compared the WGA results with those for unamplified gDNA in 10 individuals with CMML.
Materials and Methods

STUDY PARTICIPANTS AND CLINICAL SAMPLES
Bone marrow samples were obtained from 10 patients with CMML (9 male patients; median age, 70 years; range, 53-83 years) between June 2010 and August 2011. The disease in these patients was classified as CMML type 1 (n ϭ 7) or CMML type 2 (n ϭ 3) according to the 2008 WHO classification of myeloid neoplasms and acute leukemia (16 ) . Detailed clinical information is given in Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol59/issue8. Informed consent was provided according to the Declaration of Helsinki.
DNA ISOLATION AND WGA
We isolated total leukocytes from bone marrow after red cell lysis and extracted gDNA from approximately 5 ϫ 10 6 leukocytes with the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's recommendations. For comparisons, we carried out MDA technology-based WGA for each sample, with both the REPLI-g UltraFast Mini Kit (Qiagen) and the GenomiPhi DNA Amplification Kit (GE Healthcare) with 20 ng template gDNA and in accordance with manufacturer instructions. Each amplified sample was diluted into 10 volumes of diluent to generate a concentration of approximately 15-20 ng/L.
GENE SELECTION AND AMPLICON DESIGN
The 26 most commonly mutated leukemia-associated genes in AML, MDS, MPN, and MDS/MPN were selected and analyzed at known mutational hotspots or for complete coding regions (Table 1 ). In accordance with the manufacturer's (454 Life Sciences, a Roche company) recommendations for sequencing, 184 PCR amplicons were chosen to cover the candidate genes; amplicons had lengths of 300 -400 bp and an additional adapter sequence of 50 bp. Amplicons were designed to overlap and include exon/intron boundaries to permit the detection of potential splice mutations. All primers are listed in the Tables 2 and 3 in the online Data Supplement.
PCR REACTIONS
Amplicons were generated in a 25-L reaction volume with AmpliTaq Gold (Life Technologies) and either 20 ng gDNA or 1 L diluted WGA sample. GC-rich templates were amplified with the GC-RICH PCR System, dNTPack Kit (Roche Applied Science). PCR protocols and cycling conditions are given in Table 2 in the online Data Supplement. PCR products were resolved on 30 g/L agarose gels and visualized by staining with ethidium bromide. All PCR reactions were also optimized with the FastStart High Fidelity PCR System (Roche). PCR protocols and cycling conditions are given in Table 3 in the online Data Supplement.
JAK2 p.V617F SENSITIVITY CONTROLS
To test the level of detection for NGS, we prepared external controls at 8 different relative concentra-tions of a sample (100%, 50%, 20%, 10%, 5%, 1%, 0.5%, 0.1%) that harbored the nonreceptor tyrosine kinase JAK2 p.V617F mutation. Wild-type and mutant-type (MT) fragments were cloned with the TOPO TA Cloning Kit with One Shot TOP10FЈ Competent Cells (Life Technologies), followed by plasmid isolation with the Plasmid Maxi Kit (Qiagen). Controls were analyzed with conventional pyrosequencing (Pyromark Q96ID; Qiagen) and semiquantitative genotyping by amplification-refractory mutation system (ARMS) PCR (17 ) . All control amplicons were prepared in a physically separated area to avoid contaminating patient samples with plasmid.
NEXT-GENERATION SEQUENCING
NGS was performed on the 454 GS Junior platform and with 454 GS Junior Titanium chemistry for amplicon sequencing (Roche). For each of the 30 NGS runs (10 gDNA samples and 2 WGA samples for each case), we prepared 184 amplicons and 8 external JAK2 p.V617F sensitivity controls, representing 5760 individual PCR products. PCR products were purified with the Agencourt AMPure XP kit (Beckman Coulter) and quantified with the Quant-iT PicoGreen Assay (Life Technologies). PCR products were pooled for each sample and processed in a single NGS run. Pooling ratios for amplicon library preparation are listed in Tables 2 and 3 in the online Data Supplement. Before performing 454 emulsion PCR (emPCR) amplification, we purified the amplicon pool again with the Agencourt AMPure XP kit. emPCR amplification was carried out according to the manufacturer's instructions and with a 0.4 ratio of DNA copies to beads. NGS data were analyzed with the GS Amplicon Variant Analyzer (AVA) software (version 2.7; Roche). We generated both forward and reverse reads to validate the variants we detected. Filters were set to display sequence variants present in at least 1 patient at a minimum of 5% of both forward and reverse reads. Mutations were compared with published SNP data, available through the Ensembl genome browser.
SANGER SEQUENCING
To confirm the mutation in independent reactions, we also used conventional Sanger sequencing with gDNA and a 3500 Genetic Analyzer (Life Technologies) to analyze mutation-harboring amplicons detected by NGS. Amplicons were purified by adding 1 L PCR product to 2 L ExoSAP reagent, which was prepared by mixing 1 volume of Exonuclease I (New England Biolabs) and 4 volumes of Rapid Alkaline Phosphatase (Roche). Purification conditions were 37°C for 15 min, 80°C for 15 min, and a final hold at 4°C. The sequencing reaction mix was prepared by using the BigDye Terminator Cycle Sequencing Kit v1.1 (Life Technologies) according to the manufacturer's instructions.
STATISTICS
To compare results generated from gDNA and WGA samples, we analyzed all detected variants, including SNPs, silent mutations, and variants located in introns or untranslated regions. We analyzed 349 variants, with 29 -40 variants distributed per patient. For each variant, we calculated the differences between variant frequencies detected in the WGA samples and those in the corresponding gDNA sample. We determined the range of differences and absolute differences for both WGA kits to evaluate the deviation of variant frequencies detected in the WGA samples from the gDNA results. In addition, we determined mean differences in variant frequencies between WGA and gDNA samples for each patient as a means of evaluating the performance of the individual kits. We used these values with the Wilcoxon signed rank test to compare the performance of the WGA kit to that for gDNA.
Results
SENSITIVITY CONTROLS
The semiquantitative genotyping of sensitivity controls by ARMS PCR reliably detected MT gDNA at levels as low as 0.5% to 1% (see Fig. 1 in the online Data Supplement). With NGS design, we were able to detect the mutant allele in the 5% sensitivity control in every run (Table 2) ; however, the median variant frequency detected in the 5% control was below the 5% sensitivity level. Our analysis of controls with conventional pyrosequencing generated results below the expected values, with a mean result of 1.7% MT DNA in the 5% control sample (see Table 4 in the online Data Supplement).
NGS PERFORMANCE IN gDNA SAMPLES
We carried out NGS to investigate 26 candidate genes known to play a role in myeloid disorders. Each sample library was sequenced individually. We were not able to sequence CEBPA [CCAAT/enhancer binding protein (C/EBP), alpha] successfully because of insufficient fragment amplification during emPCR amplification. Fig. 1 shows a typical distribution of amplicon reads for one of the CMML samples, with the majority of reads ranging from 300 bp to 400 bp. A median of 94 935 high-quality sequencing reads (passed filter wells) were , and ZRSR2. We also observed 5 nonsense mutations (TET2), 2 deletions (TET2, SRSF2), and 1 insertion (ZRSR2). Five mutations recurred in multiple individuals. We detected 3 low-level mutations (Յ1.5%) that were present in other samples at greater than the 5% sensitivity level. We detected a total of 32 mutations in 11 genes (Table 3 ). All mutations with a variant frequency Ͼ20% were confirmed by conventional Sanger sequencing. The AVA software reported 1 deletion detected in the CBL gene of patient no. 9 as multiple inconclusive base pair deletions (see Table 5 in the online Data Supplement). Cloning of this amplicon and reanalysis by Sanger sequencing revealed a 142-bp deletion located in intron 7/8 and exon 8. Analysis of cDNA of patient no. 9 showed complete deletion of exon 8 at the transcriptional level.
NGS PERFORMANCE IN WGA SAMPLES
With WGA samples, all genes were again sequenced successfully, apart from CEBPA. The distribution of amplicon reads was 300 bp to 400 bp, in agreement with the amplicon design and with gDNA. We generated a median of 96 457 high-quality sequencing reads (passed filter wells) per individual (range, 75 386 to 101 870 reads), with a median coverage of 506 reads per amplicon and a sensitivity limit of approximately 5%. The median coverage for individual amplicons ranged from 256 to 653 reads. A median of 33.1 Mb was sequenced per sample, with the median length of reads ranging from 341 to 346 bp.
GENE MUTATIONS IN WGA SAMPLES
After artifactual variants were rejected, a total of 95 variants remained. Again, we excluded 14 polymorphisms, 4 silent mutations, and 49 variants detected in introns or untranslated regions. In addition, we excluded 4 distinct artificial variants that were detected above the 5% sensitivity limit in WGA samples only. All of these artifacts were observed more frequently in GenomiPhi-amplified samples than in REPLI-gamplified samples and were displayed as single-base pair deletions, either in the same position or directly adjacent to a single-base pair substitution in the same individual. Thus, after exclusion we observed the same 24 distinct mutations that we had already detected in gDNA samples. Four mutations recurred in multiple patients. We detected no low-level mutations (Յ1.5%) in WGA samples, however. In total, 29 mutations were detected in 11 genes (Table 3) .
COMPARISON OF VARIANTS IN gDNA AND WGA SAMPLES
We calculated the differences between gDNA and the corresponding WGA samples for all detected variant frequencies (n ϭ 349). GenomiPhi-amplified samples generated differences that ranged from Ϫ35.03% to ϩ18.67%, with a mean (SD) difference of Ϫ0.75% (5.12%). REPLI-g-amplified DNA generated a smaller range of differences in variant frequencies, from Ϫ28.19% to ϩ9.94% with a mean difference of Ϫ0.2% (4.08%) (Fig. 2) . The sum of the absolute differences in variant frequencies was higher in GenomiPhiamplified samples (⌺ ϭ 1017.2%) than in REPLI-gamplified samples (⌺ ϭ 793.6%). The analysis of mean differences in variant frequencies for individual patients (n ϭ 10) with the Wilcoxon signed rank test revealed a significant difference between gDNA and GenomiPhi-generated results (P ϭ 0.007; negative rank, n ϭ 9; positive rank, n ϭ 1). Mutations detected in gDNA samples were also detected in the matched WGA samples at comparable variant frequencies (Table 3; Fig. 3 , A-C); however, low-level mutations (Ͻ1.5%) found in gDNA were not detected in WGA samples. One mutation (TP53 exon 5, c.537AϾT, p.H180L) found in gDNA of patient no. 5 at a variant frequency marginally greater than 5% would not have been detected in the GenomiPhi-amplified sample without comparison with gDNA (Table 3 ; Fig. 3D ). Additionally, WGA samples produced slightly more false-positive variants in homopolymer regions (Ն5 bp), particularly insertions and deletions ("indels").
Discussion
Using 454 amplicon deep sequencing, we were able to analyze 25 leukemia-associated genes simultaneously in a single sequencing run. All patients except patient no. 9 displayed Ͼ1 mutation. Only 5 of 24 distinct mutations were found in multiple individuals, a finding that underscores the genetic heterogeneity of CMML. We were able to verify by Sanger sequencing all detected mutations with a variant frequency Ն20%. This In patient no. 9, NGS generated inconclusive data for CBL exon 8 (see Table 5 in the online Data Supplement). Cloning of this amplicon was cloned and reanalysis by Sanger sequencing revealed a 142-bp deletion in intron 7/8 and exon 8. result is important because false positives can be a problem with NGS. They may arise through sequencedetection errors, particularly in the form of "indels" in homopolymer regions or misincorporation of bases during the PCR. The latter problem can be minimized through the use of high-fidelity polymerases.
Our optimized PCR protocol (same master mix and cycling conditions) allows rapid amplicon generation and simplifies library preparation, despite the large number of amplicons analyzed per run. Although sequencing with the GS Junior System allows massively parallel clonal amplification of most PCR products, 454 GS Junior Titanium chemistry amplifies CEBPA inefficiently, most likely because of its high GC content (74.7%). An alternative emPCR protocol previously established for CEBPA (454 GS FLX Titanium chemistry) uses additive reagent instead of water in the emPCR master mix. This protocol increases the amount of PCR product in the amplicon library by up to 4-fold (18 ) . Beads enriched according to this protocol have also been analyzed on the GS Junior platform. Furthermore, beads carrying clonal CEBPA fragments can be combined before analysis with other beads created with regular emPCR conditions. Despite difficulties with regard to the analysis of highly GC-rich amplicons, the 454 method we have presented offers great flexibility and can be adapted to fit particular research purposes. For instance, analyzing fewer selected genes per run would increase sensitivity. Alternatively, additional amplicons can easily be added to our design.
The sequencing technology of 454 Life Sciences distinguishes itself by read lengths of high quality that are comparable to those of conventional Sanger sequencing, which is a major advantage for direct amplicon deep sequencing. Other NGS platforms, such MiSeq (Illumina) and Ion Torrent (Life Technologies), provide read lengths of only 35-151 bp but have a higher sequence output overall. The Illumina TruSeq Amplicon and Ion Torrent Ion AmpliSeq cancer panels require an input of 250 ng and 10 ng of DNA, respectively; however, such panels are not flexible, because the set of cancer-related genes and their respective coverages are predefined by the manufacturer and cannot be altered to suit specific research applications. With the targeted sequencing approach we have developed, the biology of a wide range of myeloid neoplasms can be better defined, even in the setting of a small laboratory. The high coverage achieved for individual amplicons exceeds that of most whole-genome approaches, thereby allowing sensitive deep sequencing for detecting low-level molecular aberrations that could help researchers gain insight into disease progression and into the clinical relevance of such mutations with regard to treatment response and relapse.
To monitor assay performance, we designed external JAK2 p.V617F sensitivity controls that we added to each run. To generate full quantitative data, we analyzed controls by conventional pyrosequencing. We observed a detection limit of 5% mutant allele with good assay precision and reproducibility. In keeping with the calculated sensitivity level of 5% (based on median amplicon coverage and a minimum of 25 sequencing reads harboring a particular variant), we consistently detected the JAK2 p.V617F mutation in all samples with at least 5% mutant allele when we used the 454 Sequencing System. The frequencies of detected variants were subject to small intraassay fluctuations between repeated analyses (the SDs of 30 runs for each control ranged from 0.0% to 2.9%) and deviated slightly from expected values, with median results being marginally lower than expected. Factors such as capture and emPCR biases could contribute to these small fluctuations. In a large-scale multilaboratory study on the sequencing performance of the 454 GS FLX System, repeat analyses of the same samples were also subject to assay fluctuations (19 ) . Results remained comparable, however, and detection levels were not influenced by amplicon coverage.
A challenge for most NGS systems is the large amount of input DNA required for analysis. Approxi- We detected 349 variants (variant frequencies are presented as percentages) in 10 individuals with CMML (29 -40 variants per individual). GenomiPhi-amplified samples generated differences that ranged from Ϫ35.03% to 18.67% [mean (SD), Ϫ0.75% (5.12%)] and were negatively skewed. REPLI-g-amplified DNA generated a smaller range of differences, from Ϫ28.19% to 9.94% [mean (SD), Ϫ0.2% (4.08%)]. (A), Shown are data from patient no. 3, who carried a missense mutation in RUNX1 exon 3 (c.86TϾC) encoding p.L29S. Variant frequencies were reported at 48.67%, 43.80%, and 51.49% for gDNA, GenomiPhi-amplified gDNA, and REPLI-g-amplified gDNA, respectively. (B), Shown are data from patient no. 4, who carried a nonsense mutation in TET2 exon 3 (c.1630CϾT) encoding p.R544X. Variant frequencies were 11.62%, 11.17%, and 10.29% for gDNA, GenomiPhi-amplified gDNA, and REPLI-g-amplified gDNA, respectively. (C), Shown are data from patient no. 3, who carried a 6-bp duplication in ZRSR2 exon 11 (c.1343dupGAGCCG) encoding an insertion/duplication of serine and arginine. Variant frequencies were 47.64%, 46.17%, and 39.71% for gDNA, GenomiPhi-amplified gDNA, and REPLI-g-amplified gDNA, respectively. (D), Shown are data from patient no. 5, who carried a missense mutation in TP53 exon 5 (c.537AϾT) encoding p.H180L. Variant frequencies were 5.05%, 1.89%, and 7.90% for gDNA, GenomiPhi-amplified gDNA, and REPLI-g-amplified gDNA respectively. Note that the frequency of the detected variant was below the 5% sensitivity level in the GenomiPhi-amplified sample.
Continued on page xxx mately 3.6 g gDNA is needed in the presented method to generate all 180 amplicons. The combination of NGS with WGA allows the analysis of samples that are of such great value that it is critical to preserve as much material as possible. In many cases, rare DNA or leukocyte samples have been stored for years and additional patient material cannot be obtained. Frequently, researchers need to make use of low-abundance specimens because they are the only material available for scientific investigation. Blood smears, for example, are often archived for long periods of time. If gDNA is prepared from a sample with a normal leukocyte count, 20 -120 ng can be extracted per slide, which is sufficient material for WGA (20 ) .
Various WGA methods have been developed over the years. PCR-based amplification methods such as primer extension preamplification and degenerate oligonucleotide primed PCR use various Taq polymerases, whereas the more recent MDA-based methods (GenomiPhi and REPLI-g) use ⌽29 polymerase. The proofreading activity of ⌽29 polymerase makes this enzyme less error prone than Taq polymerase (14 ) . A study that investigated various WGA methods in combination with 454 Sequencing Systems' technology to sequence 2 bacterial genomes found that MDA generated higher DNA yields than PCR-based methods (21 ) . This gain in yield is facilitated through the stranddisplacement activity of ⌽29 polymerase, which allows 
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for isothermal amplification, thereby preserving enzyme function and ultimately producing a substantially higher DNA yield than PCR-based methods, which cause a rapid decrease in enzyme activity through the multiple denaturation and annealing cycles. We also observed differences between MDA methods. The REPLI-g kit generated a higher DNA yield than the GenomiPhi kit. This difference can be attributed to the former's use of potassium hydroxide alkaline denaturation before amplification, which allows better access to priming sites than the thermaldenaturation approach used with GenomiPhi. MDAbased amplification also introduces lower amplification bias with respect to genome representation than PCR-based methods. Marginally more bias was observed in REPLI-g-amplified samples, compared with GenomiPhi samples, but the whole-genome sequencing approach and the differences in the genetic composition of bacterial DNA make it difficult to compare these results to those for targeted-sequencing approaches with human samples.
We investigated the use of WGA in combination with our targeted 454 Sequencing Systems' sequencing approach to determine whether small-scale errors and/or preferential amplification affect variant frequencies detected in WGA samples and thereby decrease genotyping accuracy. Our comparison of results generated with WGA and matched gDNA samples revealed reliable detection of mutations with WGA material. We were not able to detect low-level mutations (Յ1.5%) in WGA samples, however. A comparative analysis of all detected variants revealed only marginal differences between amplification kits. When individual differences between variant frequencies of gDNA and WGA samples were found, GenomiPhi-amplified samples showed a larger range of differences and higher total differences compared with REPLI-g samples, indicating that REPLI-g-amplified DNA generated variant frequencies at higher accuracy compared with gDNA results. When we compared mean differences in variant frequencies for individual samples, we observed a significant difference between gDNA-and GenomiPhi-generated results (P ϭ 0.007; negative rank, n ϭ 9; positive rank, n ϭ 1). These results are in keeping with the slightly negatively skewed range of differences between the observed GenomiPhi and gDNA variant frequencies. An overall decrease in variant frequencies might cause some mutations to remain undetected, as we observed with the TP53 mutation detected in patient no. 5. It is important to note, however, that intraassay variation may also contribute to fluctuations that might cause low-level mutations to remain undetected. In terms of general NGS data, gDNA and corresponding WGA samples generated comparable coverages with an assay sensitivity of approximately 5%. Despite the proofreading activity of the ⌽29 polymerase, preamplification of samples through MDA slightly increase false-positive variations, particularly in homopolymer regions. Falsepositive single-base pair deletions in the same position or directly adjacent to a single-base pair substitution have also been observed. To address the issue of sequence errors, we recommend setting the "Min" value to 5.0% and choosing the "forward and reverse" filter on the Variants Tab of AVA software, in addition to verifying variants through Sanger sequencing.
In summary, the 454 Sequencing System's method we have presented allows accurate, sensitive analysis of the 25 most commonly mutated leukemia-associated genes. We expect this method will help researchers unravel associations between mutations in different pathways without the need of large amounts of patient material. 
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